OBJECTIVE: The interaction of platelets with low density lipoprotein (LDL) contributes to the development of cardiovascular disease. Platelets are activated by native LDL (nLDL) through apoE Receptor 2' (apoER2')-mediated signaling to p38(MAPK) and by oxidized LDL (oxLDL) through lysophosphatidic acid (LPA) signaling to Rho A and Ca2+. Here we report a new mechanism for platelet activation by oxLDL. METHODS AND RESULTS: Oxidation of nLDL increases p38(MAPK) activation through a mechanism that is (1) independent of LPA, and (2) unlike nLDL-signaling not desensitized by prolonged platelet-LDL contact or inhibited by receptor-associated protein or chondroitinase ABC. Antibodies against scavenger receptors CD36 and SR-A alone fail to block p38(MAPK) activation by oxLDL but combined blockade inhibits p38(MAPK) by >40% and platelet adhesion to fibrinogen under flow by >60%. Mouse platelets deficient in either CD36 or SR-A show normal p38(MAPK) activation by oxLDL but combined deficiency of CD36 and SR-A disrupts oxLDL-induced activation of p38(MAPK) by >70%. CONCLUSION: These findings reveal a novel platelet-activating pathway stimulated by oxLDL that is initiated by the combined action of CD36 and SR-A.
OBJECTIVE: The interaction of platelets with low density lipoprotein (LDL) contributes to the development of cardiovascular disease. Platelets are activated by native LDL (nLDL) through apoE Receptor 2' (apoER2')-mediated signaling to p38(MAPK) and by oxidized LDL (oxLDL) through lysophosphatidic acid (LPA) signaling to Rho A and Ca2+. Here we report a new mechanism for platelet activation by oxLDL. METHODS AND RESULTS: Oxidation of nLDL increases p38(MAPK) activation through a mechanism that is (1) independent of LPA, and (2) unlike nLDL-signaling not desensitized by prolonged platelet-LDL contact or inhibited by receptor-associated protein or chondroitinase ABC. Antibodies against scavenger receptors CD36 and SR-A alone fail to block p38(MAPK) activation by oxLDL but combined blockade inhibits p38(MAPK) by >40% and platelet adhesion to fibrinogen under flow by >60%. Mouse platelets deficient in either CD36 or SR-A show normal p38(MAPK) activation by oxLDL but combined deficiency of CD36 and SR-A disrupts oxLDL-induced activation of p38(MAPK) by >70%. CONCLUSION: These findings reveal a novel platelet-activating pathway stimulated by oxLDL that is initiated by the combined action of CD36 and SR-A.
Authors: Arunima Ghosh; Gurunathan Murugesan; Kan Chen; Li Zhang; Qing Wang; Maria Febbraio; Rita Marie Anselmo; Kandice Marchant; John Barnard; Roy L Silverstein Journal: Blood Date: 2011-04-08 Impact factor: 22.113
Authors: Dianne E van der Wal; Eelo Gitz; Vivian X Du; Kimberly S L Lo; Cornelis A Koekman; Sabine Versteeg; Jan Willem N Akkerman Journal: Haematologica Date: 2012-02-27 Impact factor: 9.941
Authors: Afrouz Yousefi; Marianne Lauwers; Reka Nemes; Thijs van Holten; Negar Babae; Mark Roest; Gert Storm; Raymond Schiffelers; Enrico Mastrobattista Journal: Pharm Res Date: 2014-05-20 Impact factor: 4.200
Authors: Ernst J A Steller; Danielle A Raats; Jan Koster; Bert Rutten; Klaas M Govaert; Benjamin L Emmink; Nikol Snoeren; Sander R van Hooff; Frank C P Holstege; Coen Maas; Inne H M Borel Rinkes; Onno Kranenburg Journal: Neoplasia Date: 2013-02 Impact factor: 5.715